Deborah DeRyckere

Identification and characterization of transcription factor target genes using gene-targeted mice.

Characterization of transcriptional regulation during negative selection in vivo.

E2F1 and E2F2 are differentially required for homeostasis-driven and antigen-induced T cell proliferation in vivo.

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.

Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.

Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.

Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

UNC1062, a new and potent Mer inhibitor.

Molecular Pathways: MERTK Signaling in Cancer.

Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

UNC569, a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.